DDR on DTC: Axiron

Share this article:
Deborah Dick-Rath
Deborah Dick-Rath

The new campaign for Lilly's low testosterone treatment, Axiron, is a classic in both form and execution. The 60-second TV ad is highly targeted and assumptive—it does not explain the condition or how someone may be suffering—but charges right at the viewer with a solution by frame 3. And that's after a product demo. This is very effective for the tone and the brand context the ad sets.

We applaud the way this commercial sets up the issue and benefit so quickly. This usually takes more time in a DTC ad because advertisers have to “educate” viewers about a condition or disease before introducing their drug or device problem-solver. In this case, Lilly has more to do— they also need to sell the unique underarm application, and they do this with a great iconic gesture that is reinforced throughout the commercial as the sufferer repeatedly lifts his arm. We also see the raised arm in a classic Greek statue of a very athletic man who probably never heard of “low T.”

 

Speaking of “low T,” this category now has two distinct DTC entrants. Axiron's competition educates the target audience about the condition and offers some absolution—“It wasn't me. It was a number.” But Lilly assumes that its audience is ready for a bull's-eye message. Or, as a classic ad man once said the job of the commercial is threefold: “Tell 'em what you're going to tell 'em. Tell 'em. Then tell them what you told ‘em.” Yes, classic.


Deborah Dick-Rath is the president of Epic Proportions, a healthcare communications consultancy. She can be reached at deborahdrath@optonline.net
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.